{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:10:45Z","timestamp":1762161045353,"version":"3.40.4"},"reference-count":108,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,7]],"date-time":"2014-03-07T00:00:00Z","timestamp":1394150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.lfs.2014.02.025","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T14:45:36Z","timestamp":1393944336000},"page":"141-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Endothelin receptor antagonists in clinical research \u2014 Lessons learned from preclinical and clinical kidney studies"],"prefix":"10.1016","volume":"118","author":[{"given":"Christoph","family":"Reichetzeder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Tsuprykov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berthold","family":"Hocher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0280","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1172\/JCI200421064","article-title":"Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention","volume":"114","author":"Ahn","year":"2004","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.lfs.2014.02.025_bb0430","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1093\/ndt\/gfn346","article-title":"Japanese haemodialysis anaemia management practices and outcomes (1999\u20132006): results from the DOPPS","volume":"23","author":"Akizawa","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"15","key":"10.1016\/j.lfs.2014.02.025_bb0045","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/01.CIR.0000144462.08345.B9","article-title":"Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction","volume":"110","author":"Amiri","year":"2004","journal-title":"Circulation"},{"issue":"13\u201314","key":"10.1016\/j.lfs.2014.02.025_bb0230","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.lfs.2012.01.011","article-title":"Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)","volume":"91","author":"Andress","year":"2012","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0245","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1152\/physrev.00017.2003","article-title":"Neuroendocrine control of body fluid metabolism","volume":"84","author":"Antunes-Rodrigues","year":"2004","journal-title":"Physiol Rev"},{"issue":"8","key":"10.1016\/j.lfs.2014.02.025_bb0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1139\/Y08-059","article-title":"Endothelin: 20years from discovery to therapy. This article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin","volume":"86","author":"Barton","year":"2008","journal-title":"Can J Physiol Pharmacol"},{"issue":"5","key":"10.1016\/j.lfs.2014.02.025_bb0065","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1681\/ASN.V115835","article-title":"Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis","volume":"11","author":"Barton","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.lfs.2014.02.025_bb0260","first-page":"653","article-title":"Profile of past and current clinical trials involving endothelin receptor antagonists: the novel \u201c-sentan\u201d class of drug","volume":"231","author":"Battistini","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1523-1755.1998.00011.x","article-title":"Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy","volume":"54","author":"Benigni","year":"1998","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.lfs.2014.02.025_bb0125","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1517\/13543784.13.11.1419","article-title":"The potential of endothelin antagonism as a therapeutic approach","volume":"13","author":"Benigni","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.lfs.2014.02.025_bb0390","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00007890-199909270-00005","article-title":"Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist","volume":"68","author":"Braun","year":"1999","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.lfs.2014.02.025_bb0400","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/ndt\/14.8.1881","article-title":"Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats","volume":"14","author":"Brochu","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"5 Suppl. 1","key":"10.1016\/j.lfs.2014.02.025_bb0335","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.1097\/00005344-200036051-00090","article-title":"Effects of A-192621.1, a specific endothelin-B antagonist, on intrarenal hemodynamic responses to endothelin-1","volume":"36","author":"Brodsky","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0370","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1159\/000188951","article-title":"Blockade of radiocontrast-induced nephrotoxicity by the endothelin receptor antagonist, SB 209670","volume":"72","author":"Brooks","year":"1996","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0325","doi-asserted-by":"crossref","first-page":"F1063","DOI":"10.1152\/ajprenal.90321.2008","article-title":"Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct","volume":"295","author":"Bugaj","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.lfs.2014.02.025_bb0365","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/ki.1993.371","article-title":"Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction","volume":"44","author":"Cantley","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.lfs.2014.02.025_bb0410","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000328701","article-title":"Endothelin in polycystic kidney disease","volume":"172","author":"Chang","year":"2011","journal-title":"Contrib Nephrol"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0405","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1681\/ASN.2006090994","article-title":"Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease","volume":"18","author":"Chang","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.lfs.2014.02.025_bb0480","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1242\/dev.125.5.813","article-title":"Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice","volume":"125","author":"Clouthier","year":"1998","journal-title":"Development"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0022-3565(25)22357-6","article-title":"Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist","volume":"270","author":"Clozel","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.lfs.2014.02.025_bb0520","first-page":"S90","article-title":"Edema in pregnancy","volume":"59","author":"Davison","year":"1997","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0130","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.2005121256","article-title":"The endothelin system and its antagonism in chronic kidney disease","volume":"17","author":"Dhaun","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lfs.2014.02.025_bb0205","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000328704","article-title":"Endothelin antagonism in patients with nondiabetic chronic kidney disease","volume":"172","author":"Dhaun","year":"2011","journal-title":"Contrib Nephrol"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0022-3565(24)39242-0","article-title":"Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model","volume":"293","author":"Dhein","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"5 Suppl. 1","key":"10.1016\/j.lfs.2014.02.025_bb0415","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1097\/00005344-200036051-00058","article-title":"Regulation of the renal endothelin system in the two-kidney, one clip renal hypertensive rat","volume":"36","author":"Diekmann","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0195","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00005344-200307000-00008","article-title":"Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat","volume":"42","author":"Ding","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"issue":"15","key":"10.1016\/j.lfs.2014.02.025_bb0435","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003088-200443150-00003","article-title":"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist","volume":"43","author":"Dingemanse","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0340","doi-asserted-by":"crossref","first-page":"F144","DOI":"10.1152\/ajprenal.0064.2001","article-title":"Role of cytochrome P-450 arachidonate metabolites in endothelin signaling in rat proximal tubule","volume":"282","author":"Escalante","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"issue":"10","key":"10.1016\/j.lfs.2014.02.025_bb0345","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1097\/00004872-200110000-00013","article-title":"Effects of ET(A)- and ET(B)-receptor antagonists on regional kidney blood flow, and responses to intravenous endothelin-1, in anaesthetized rabbits","volume":"19","author":"Evans","year":"2001","journal-title":"J Hypertens"},{"issue":"9","key":"10.1016\/j.lfs.2014.02.025_bb0460","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1096\/fj.10-159483","article-title":"Endothelin B receptor stimulation inhibits suicidal erythrocyte death","volume":"24","author":"F\u00f6ller","year":"2010","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.lfs.2014.02.025_bb0155","doi-asserted-by":"crossref","first-page":"F1448","DOI":"10.1152\/ajprenal.00340.2009","article-title":"Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes","volume":"297","author":"Gagliardini","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2 Pt 2","key":"10.1016\/j.lfs.2014.02.025_bb0315","first-page":"F451","article-title":"Regulation of amiloride-sensitive Na+ channels by endothelin-1 in distal nephron cells","volume":"271","author":"Gallego","year":"1996","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.lfs.2014.02.025_bb0285","doi-asserted-by":"crossref","first-page":"F912","DOI":"10.1152\/ajprenal.00432.2004","article-title":"Collecting duct-specific knockout of endothelin-1 alters vasopressin regulation of urine osmolality","volume":"288","author":"Ge","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0290","doi-asserted-by":"crossref","first-page":"F692","DOI":"10.1152\/ajprenal.00100.2005","article-title":"Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure","volume":"289","author":"Ge","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.lfs.2014.02.025_bb0295","doi-asserted-by":"crossref","first-page":"F1274","DOI":"10.1152\/ajprenal.00190.2006","article-title":"Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention","volume":"291","author":"Ge","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.lfs.2014.02.025_bb0300","doi-asserted-by":"crossref","first-page":"F1635","DOI":"10.1152\/ajprenal.90279.2008","article-title":"Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention","volume":"295","author":"Ge","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0505","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MNH.0b013e328350094b","article-title":"Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications","volume":"21","author":"George","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"45","key":"10.1016\/j.lfs.2014.02.025_bb0320","doi-asserted-by":"crossref","first-page":"42610","DOI":"10.1074\/jbc.M106919200","article-title":"SRC family kinases mediate epithelial Na+ channel inhibition by endothelin","volume":"276","author":"Gilmore","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lfs.2014.02.025_bb0250","unstructured":"Grass M. Sicherheit und Vertr\u00e4glichkeit, Pharmakokinetik und Pharmakodynamik des selektiven Endothelin-A-Rezeptor-Antagonisten SPP301 bei oraler Mehrfachadministration an gesunde, m\u00e4nnliche Probanden , 2001."},{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0355","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ki.1991.255","article-title":"Early renal medullary hypoxic injury from radiocontrast and indomethacin","volume":"40","author":"Heyman","year":"1991","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0015","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0006-291X(92)91222-C","article-title":"Intracellular distribution of endothelin-1 receptors in rat liver cells","volume":"184","author":"Hocher","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0070","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/01.HYP.28.2.196","article-title":"Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene","volume":"28","author":"Hocher","year":"1996","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0525","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.1996.tb15390.x","article-title":"Paracrine renal endothelin system in rats with liver cirrhosis","volume":"118","author":"Hocher","year":"1996","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.lfs.2014.02.025_bb0035","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1172\/JCI119297","article-title":"Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension","volume":"99","author":"Hocher","year":"1997","journal-title":"J Clin Invest"},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2014.02.025_bb0140","doi-asserted-by":"crossref","first-page":"S492","DOI":"10.1097\/00005344-199800001-00141","article-title":"Renal endothelin system in diabetes: comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism","volume":"31","author":"Hocher","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"10.1016\/j.lfs.2014.02.025_bb0380","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1681\/ASN.V971169","article-title":"Renal endothelin system in polycystic kidney disease","volume":"9","author":"Hocher","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.lfs.2014.02.025_bb0420","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/00004872-200018120-00015","article-title":"ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats","volume":"18","author":"Hocher","year":"2000","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000045906","article-title":"Effects of endothelin receptor antagonists on the progression of diabetic nephropathy","volume":"87","author":"Hocher","year":"2001","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0385","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.ASN.0000042165.63601.65","article-title":"ETA receptor blockade induces tubular cell proliferation and cyst growth in rats with polycystic kidney disease","volume":"14","author":"Hocher","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004872-200401000-00020","article-title":"In-vivo interaction of nitric oxide and endothelin","volume":"22","author":"Hocher","year":"2004","journal-title":"J Hypertens"},{"issue":"8","key":"10.1016\/j.lfs.2014.02.025_bb0210","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1681\/ASN.V1181498","article-title":"Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans","volume":"11","author":"Honing","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.lfs.2014.02.025_bb0490","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/0092-8674(94)90017-5","article-title":"Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice","volume":"79","author":"Hosoda","year":"1994","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0350","doi-asserted-by":"crossref","first-page":"F568","DOI":"10.1152\/ajprenal.00613.2012","article-title":"Endothelin-1 inhibits sodium reabsorption by ET(A) and ET(B) receptors in the mouse cortical collecting duct","volume":"305","author":"Jeanette Lynch","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0545","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1161\/HYPERTENSIONAHA.110.163972","article-title":"Endothelin-converting enzyme\/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner","volume":"57","author":"Kalk","year":"2011","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.lfs.2014.02.025_bb0500","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1517\/14656560903061275","article-title":"Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension","volume":"10","author":"Kingman","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl. 7A","key":"10.1016\/j.lfs.2014.02.025_bb0425","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/j.amjmed.2003.12.008","article-title":"Prevalence and outcomes of anemia in cancer: a systematic review of the literature","volume":"116","author":"Knight","year":"2004","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.lfs.2014.02.025_bb0190","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ki.2009.203","article-title":"Biology of endothelin receptors in the collecting duct","volume":"76","author":"Kohan","year":"2009","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0135","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MNH.0b013e328335f91f","article-title":"Endothelin, hypertension and chronic kidney disease: new insights","volume":"19","author":"Kohan","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.lfs.2014.02.025_bb0275","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000328687","article-title":"Endothelin and collecting duct sodium and water transport","volume":"172","author":"Kohan","year":"2011","journal-title":"Contrib Nephrol"},{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0175","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bcp.12064","article-title":"Endothelin antagonists for diabetic and non-diabetic chronic kidney disease","volume":"76","author":"Kohan","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0215","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin\u2013angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"13\u201314","key":"10.1016\/j.lfs.2014.02.025_bb0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.lfs.2012.07.034","article-title":"Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?","volume":"91","author":"Kohan","year":"2012","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.lfs.2014.02.025_bb0440","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijcard.2010.04.038","article-title":"Association of anemia and long-term survival in patients with pulmonary hypertension","volume":"150","author":"Krasuski","year":"2011","journal-title":"Int J Cardiol"},{"issue":"6473","key":"10.1016\/j.lfs.2014.02.025_bb0465","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/368703a0","article-title":"Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1","volume":"368","author":"Kurihara","year":"1994","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0470","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1172\/JCI118033","article-title":"Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1","volume":"96","author":"Kurihara","year":"1995","journal-title":"J Clin Invest"},{"issue":"Suppl. 3","key":"10.1016\/j.lfs.2014.02.025_bb0475","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00005344-199506263-00005","article-title":"Impaired development of the thyroid and thymus in endothelin-1 knockout mice","volume":"26","author":"Kurihara","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"10.1016\/j.lfs.2014.02.025_bb0110","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000174251","article-title":"Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass","volume":"20","author":"Larivi\u00e8re","year":"1997","journal-title":"Kidney Blood Press Res"},{"issue":"10","key":"10.1016\/j.lfs.2014.02.025_bb0050","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1161\/ATVBAHA.113.302028","article-title":"Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice","volume":"33","author":"Li","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.lfs.2014.02.025_bb0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s001099900026","article-title":"Transgenic rats expressing the human ET-2 gene: a model for the study of endothelin actions in vivo","volume":"77","author":"Liefeldt","year":"1999","journal-title":"J Mol Med"},{"issue":"5","key":"10.1016\/j.lfs.2014.02.025_bb0455","doi-asserted-by":"crossref","first-page":"R198","DOI":"10.1186\/cc11686","article-title":"Endothelin-receptor antagonists for aneurysmal subarachnoid hemorrhage: an updated meta-analysis of randomized controlled trials","volume":"16","author":"Ma","year":"2012","journal-title":"Crit Care"},{"issue":"3","key":"10.1016\/j.lfs.2014.02.025_bb0220","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.lfs.2014.02.025_bb0360","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1681\/ASN.V251041","article-title":"Radiocontrast increases plasma and urinary endothelin","volume":"2","author":"Margulies","year":"1991","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0031-6997(25)06781-X","article-title":"International Union of Pharmacology nomenclature of endothelin receptors","volume":"46","author":"Masaki","year":"1994","journal-title":"Pharmacol Rev"},{"issue":"10","key":"10.1016\/j.lfs.2014.02.025_bb0240","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.tem.2005.10.007","article-title":"The endocrine function of the heart","volume":"16","author":"McGrath","year":"2005","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.lfs.2014.02.025_bb0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000168707","article-title":"Immunohistochemical distribution of endothelin in biopsies of pediatric nephrotic syndrome","volume":"14","author":"Murer","year":"1994","journal-title":"Am J Nephrol"},{"issue":"Suppl. 2","key":"10.1016\/j.lfs.2014.02.025_bb0185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2362.2009.02121.x","article-title":"Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence","volume":"39","author":"Neuhofer","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"10.1016\/j.lfs.2014.02.025_bb0515","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1139\/Y08-057","article-title":"Effect of the putative novel selective ETA-receptor antagonist HJP272, a 1,3,6-trisubstituted-2-carboxy-quinol-4-one, on infection-mediated premature delivery","volume":"86","author":"Olgun","year":"2008","journal-title":"Can J Physiol Pharmacol"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ki.1993.53","article-title":"Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression","volume":"43","author":"Orisio","year":"1993","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0395","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1681\/ASN.V102387","article-title":"The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the \u201cFisher to Lewis\u201d model","volume":"10","author":"Orth","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.lfs.2014.02.025_bb0310","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1681\/ASN.2009080885","article-title":"Endothelin-1 inhibits the epithelial Na+ channel through betaPix\/14-3-3\/Nedd4-2","volume":"21","author":"Pavlov","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.lfs.2014.02.025_bb0450","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lfs.2014.02.025_bb0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/ndt\/18.3.479","article-title":"Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice","volume":"18","author":"Quaschning","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.lfs.2014.02.025_bb0100","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1681\/ASN.2006050541","article-title":"Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic\/endothelial nitric oxide synthase knockout mice","volume":"18","author":"Quaschning","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lfs.2014.02.025_bb0270","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000328703","article-title":"Endothelin receptor blockade in patients with diabetic nephropathy","volume":"172","author":"Rabelink","year":"2011","journal-title":"Contrib Nephrol"},{"issue":"3","key":"10.1016\/j.lfs.2014.02.025_bb0200","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s00125-011-2415-y","article-title":"The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial","volume":"55","author":"Rafnsson","year":"2012","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.lfs.2014.02.025_bb0085","first-page":"323","article-title":"Urinary endothelin in glomerulonephritis patients with normal renal function","volume":"41","author":"Roccatello","year":"1994","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/jpet.111.178988","article-title":"Distinct actions of endothelin A-selective versus combined endothelin A\/B receptor antagonists in early diabetic kidney disease","volume":"338","author":"Saleh","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1681\/ASN.2006030208","article-title":"Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism","volume":"18","author":"Sasser","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.lfs.2014.02.025_bb0330","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/HYPERTENSIONAHA.107.108126","article-title":"Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide","volume":"51","author":"Schneider","year":"2008","journal-title":"Hypertension"},{"issue":"7\u20138","key":"10.1016\/j.lfs.2014.02.025_bb0550","first-page":"507","article-title":"Renoprotective effects of combined endothelin-converting enzyme\/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage","volume":"57","author":"Sharkovska","year":"2011","journal-title":"Clin Lab"},{"issue":"6761","key":"10.1016\/j.lfs.2014.02.025_bb0485","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/990040","article-title":"The temporal requirement for endothelin receptor-B signalling during neural crest development","volume":"402","author":"Shin","year":"1999","journal-title":"Nature"},{"issue":"Pt 3","key":"10.1016\/j.lfs.2014.02.025_bb0055","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1113\/jphysiol.2007.131201","article-title":"Cell-type specific interaction of endothelin and the nitric oxide system: pattern of prepro-ET-1 expression in kidneys of L-NAME treated prepro-ET-1 promoter-lacZ-transgenic mice","volume":"581","author":"Slowinski","year":"2007","journal-title":"J Physiol (Lond)"},{"issue":"2\u20133","key":"10.1016\/j.lfs.2014.02.025_bb0495","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.lfs.2003.09.027","article-title":"Pharmacological knockout of endothelin ET(A) receptors","volume":"74","author":"Taniguchi","year":"2003","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0510","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1071-5576(00)00119-2","article-title":"Differential effects of endothelin A and B receptor antagonism on fetal growth in normal and nitric oxide-deficient rats","volume":"8","author":"Thaete","year":"2001","journal-title":"J Soc Gynecol Investig"},{"issue":"16","key":"10.1016\/j.lfs.2014.02.025_bb0060","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.CIR.99.16.2185","article-title":"Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats","volume":"99","author":"Tharaux","year":"1999","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2014.02.025_bb0235","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/01.fjc.0000166208.12297.8d","article-title":"Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats","volume":"44","author":"Th\u00f6ne-Reinke","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"author":"TRACLEER\u00ae","key":"10.1016\/j.lfs.2014.02.025_bb0255"},{"issue":"10","key":"10.1016\/j.lfs.2014.02.025_bb0445","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1161\/STROKEAHA.112.666693","article-title":"Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update","volume":"43","author":"Vergouwen","year":"2012","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.lfs.2014.02.025_bb0535","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/HJH.0b013e3283450770","article-title":"Endothelin-1 overexpression restores diastolic function in eNOS knockout mice","volume":"29","author":"Vignon-Zellweger","year":"2011","journal-title":"J Hypertens"},{"issue":"13\u201314","key":"10.1016\/j.lfs.2014.02.025_bb0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.lfs.2012.03.026","article-title":"Endothelin and endothelin receptors in the renal and cardiovascular systems","volume":"91","author":"Vignon-Zellweger","year":"2012","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2047-783X-14-1-1","article-title":"Pathophysiology of the endothelin system \u2014 lessons from genetically manipulated animal models","volume":"14","author":"Von Websky","year":"2009","journal-title":"Eur J Med Res"},{"issue":"4","key":"10.1016\/j.lfs.2014.02.025_bb0375","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1046\/j.1523-1755.2000.00012.x","article-title":"Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism","volume":"57","author":"Wang","year":"2000","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0160","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00125-009-1540-3","article-title":"The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice","volume":"53","author":"Watson","year":"2010","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.lfs.2014.02.025_bb0540","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1179\/016164111X12881719352534","article-title":"Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival","volume":"33","author":"Wengenmayer","year":"2011","journal-title":"Neurol Res"},{"issue":"3","key":"10.1016\/j.lfs.2014.02.025_bb0225","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.lfs.2014.02.025_bb0530","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hep.21940","article-title":"Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome","volume":"47","author":"Wong","year":"2008","journal-title":"Hepatology"},{"issue":"6 Pt 1","key":"10.1016\/j.lfs.2014.02.025_bb0305","doi-asserted-by":"crossref","first-page":"C1101","DOI":"10.1152\/ajpcell.1989.257.6.C1101","article-title":"Endothelin, a peptide inhibitor of Na(+)\u2013K(+)-ATPase in intact renaltubular epithelial cells","volume":"257","author":"Zeidel","year":"1989","journal-title":"Am J Physiol"},{"issue":"5","key":"10.1016\/j.lfs.2014.02.025_bb0165","doi-asserted-by":"crossref","first-page":"F1114","DOI":"10.1152\/ajprenal.00122.2011","article-title":"Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes","volume":"301","author":"Zoja","year":"2011","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320514002811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320514002811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:01:07Z","timestamp":1746144067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320514002811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0024320514002811"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2014.02.025","relation":{},"ISSN":["0024-3205"],"issn-type":[{"type":"print","value":"0024-3205"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endothelin receptor antagonists in clinical research \u2014 Lessons learned from preclinical and clinical kidney studies","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2014.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}